Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 31, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 1,600,000 Ordinary Shares on August 31, 2012.
- Price Range: Highest price paid was 1,448.0 pence per share; lowest price paid was 1,428.0 pence per share.
- Treasury Holdings (Settled): 498,408,927 shares (9.11% of total issued share capital).
- Treasury Holdings (Including Unsettled): 503,008,927 shares (10.11% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,973,803,890 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,600,000 shares on August 31, 2012. Consequently, the percentage of shares held in Treasury increased to 10.11% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (498,408,927 settled vs. 503,008,927 including unsettled) for accurate voting rights calculations.
- Confirm the denominator for disclosure obligations under the Financial Services Authority's Disclosure and Transparency Rules is 4,973,803,890 shares.
- Note that this filing does not contain operational or financial performance data for the period.